ArticleFrontiers in public health2023
The emergence of carbapenemase-producing
Article in Frontiers in public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 9 citations in OpenAlex.
- Extended-Spectrum β-Lactamase-ProducingAnimals : an open access journal from MDPI · 2026Article
- Wildlife as a reservoir of OXA-48-like carbapenemase-producing Enterobacterales.Microbiology spectrum · 2026Article
- Contemporary multicentre analysis of carbapenemases distribution among clinical carbapenem-resistant Enterobacterales in Lebanon.JAC-antimicrobial resistance · 2026Article
- Article
- Carbapenem and colistin-resistantJAC-antimicrobial resistance · 2026Article
- Resistance to novel antimicrobial agents among NDM-and OXA-48-producing Carbapenem-resistant Enterobacterales in Lebanon.Frontiers in cellular and infection microbiology · 2026Article
- Evidence of transmission and dissemination of diverseApplied and environmental microbiology · 2025Article
- First documented extended-spectrum β-lactamase producingAnnals of medicine and surgery (2012) · 2025Article
- Molecular characterization of ESBL- and carbapenemase-producing Enterobacteriaceae isolated from cats in Lebanon.BMC microbiology · 2025Article
- Molecular Epidemiological Surveillance of Carbapenem-Resistant Gram-Negative Bacteria in Southern Lebanon.Antibiotics (Basel, Switzerland) · 2025Article
- Phenotypic, Targeted Genotypic, and Antimicrobial Susceptibility Profiling of Extended-Spectrum β-Lactamase Production and Exclusive blaJournal of clinical laboratory analysis · 2025Article
- Molecular characterization of carbapenem and ceftazidime-avibactam-resistant Enterobacterales and horizontal spread ofFrontiers in cellular and infection microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carbapenem- and extended-spectrum cephalosporin-resistant Materials and methods: Non-duplicate clinical ESCR-E or CR-E isolates ( Results: Using the Kirby-Bauer disk diffusion assay, only 90 isolates out of the 188 isolates that were collected based on their initial routine susceptibility profile by the three participating hospitals could be confirmed as ESCR-E or CR-E isolates and were included in this study. This collection comprised Conclusion: This study highlighted the emergence and broad dissemination of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.